Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guyana Health Review.
Press releases published on July 3, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
GlobeNewswire
·
July 3, 2025
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform OBT receives milestone payment associated with advance of drug candidate Oxford, …
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
GlobeNewswire
·
July 3, 2025
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Egham, UK – 03 July 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for …
Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises
GlobeNewswire
·
July 3, 2025
New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight …
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
GlobeNewswire
·
July 3, 2025
Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date …
Theratechnologies conclut un accord définitif en vue de son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
GlobeNewswire
·
July 3, 2025
Une offre de 3,01 $ US en espèces plus un droit conditionnel à la valeur représentant des paiements supplémentaires totaux potentiels pouvant atteindre 1,19 $ US par action La contrepartie initiale et la contrepartie totale en espèces potentielles …